Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials

PURPOSE: Epidermal growth factor receptor inhibitors such as panitumumab are associated with characteristic skin toxicities. We summarise data from three panitumumab clinical trials to investigate the potential impact of skin toxicity on quality of life (QoL) in patients with metastatic colorectal c...

Descripción completa

Detalles Bibliográficos
Autores principales: Koukakis, Reija, Gatta, Francesca, Hechmati, Guy, Siena, Salvatore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010834/
https://www.ncbi.nlm.nih.gov/pubmed/27083443
http://dx.doi.org/10.1007/s11136-016-1288-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010834/
https://www.ncbi.nlm.nih.gov/pubmed/27083443
http://dx.doi.org/10.1007/s11136-016-1288-4

Ejemplares similares